Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tarsus Pharmaceuticals Inc 15440 LAGUNA CANYON ROAD SUITE 160 IRVINE CA 92618 USA

www.tarsusrx.com Employees: 323 P: 949-418-1801

Sector:

Medical

Description:

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif.

Key Statistics

Overview:

Market Capitalization, $K 2,782,108
Enterprise Value, $K 2,759,138
Shares Outstanding, K 42,449
Float, K 38,641
% Float 91.03%
Short Interest, K 5,813
Short Float 13.69%
Days to Cover 10.69
Short Volume Ratio 0.61
% of Insider Shareholders 8.97%
% of Institutional Shareholders 90.01%

Financials:

Annual Sales, $ 182,950 K
Annual Net Income, $ -115,550 K
Last Quarter Sales, $ 118,700 K
Last Quarter Net Income, $ -12,590 K
EBIT, $ -87,410 K
EBITDA, $ -89,920 K

Growth:

1-Year Return 32.27%
3-Year Return 334.04%
5-Year Return 80.80%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.30 on 11/04/25
Next Earnings Date 02/23/26 [AMC]
Earnings Per Share ttm -2.02
EPS Growth vs. Prev Qtr 37.50%
EPS Growth vs. Prev Year 50.82%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

TARS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 51.60
Price/Earnings to Growth 0.91
Return-on-Equity % -26.29%
Return-on-Assets % -17.02%
Profit Margin % -63.16%
Debt/Equity 0.22
Price/Sales 7.29
Price/Cash Flow N/A
Price/Book 7.95
Book Value/Share 7.89
Interest Coverage -13.72
60-Month Beta 0.57
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar